
S&P/ASX 200 today – CCP, VUL & TAH shares in focus
The S&P/ASX 200 (INDEXASX:XJO) is heading for a positive open
Rask Media > CSL Limited (ASX:CSL) > Page 23
CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
The S&P/ASX 200 (INDEXASX:XJO) is heading for a positive open
The S&P/ASX 200 (INDEXASX:XJO) is set to charge higher when
The CSL Limited (ASX:CSL) share price is close to a
President elect Joe Biden has revealed a US$1.9 trillion healthcare
CSL Limited (ASX:CSL) shares could be an interesting idea for
Looking for the best Australian shares ETFs of 2021? There
My top 5 ASX ETFs for a diversified portfolio: iShares
The S&P/ASX 200 (INDEXASX: XJO) is expected to open flat
CSL Limited (ASX:CSL) announced some disappointing UQ COVID-19 vaccine news
Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best insights.